Wells Fargo Initiates Coverage On Scribe Therapeutics with Overweight Rating, Announces Price Target of $60
Benzinga Newsdesk 2 months ago
NewsInitiationAnalyst RatingsPrice Target
Wells Fargo analyst Yanan Zhu initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Overweight rating and announces Price Target of $60.
Wells Fargo analyst Yanan Zhu initiates coverage on Scribe Therapeutics (NASDAQ:SCTX) with a Overweight rating and announces Price Target of $60.